-
11.发明公开아다만틸기를 갖는 헤테로고리 카복스아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 有权具有金刚烷基的杂环羧酰胺衍生物，其制备方法以及含有该化合物作为活性成分的药物组合物
公开(公告)号：KR1020170079939A
公开(公告)日：2017-07-10
申请号：KR1020150191020
申请日：2015-12-31
Inventor： 김기영 , 이상달 , 김희연 , 정원훈 , 안진희 , 강승규 , 서지희 , 배명애 , 신대섭 , 유욱준 , 이진수 , 김원태 , 정지성 , 김영훈 , 배현주 , 이주희 , 양은영 , 오세환 , 김영하
IPC: C07D277/04 , C07D417/06 , C07D413/06 , C07D409/06 , C07D279/12 , C07D265/30
Abstract: 본발명은 11β-하이드록시스테로이드디하이드로게나제타입 1(11-hydroxystreroid dehydrogenase type1,11-HSD1)의활성을억제하는하기화학식 1로표시되는아다만틸기를갖는헤테로고리카복스아미드유도체, 그의프로드럭, 그의용매화물, 그의입체이성질체또는약제학적으로허용가능한그의염, 이의제조방법및 이를유효성분으로함유하는약제학적조성물에관한것이다. [화학식 1]상기화학식 1에서, W, X, R, R, L, a 및 b은발명의상세한설명에서정의한바와같다.
Abstract translation: 权利要求抑制（11-hydroxystreroid脱氢酶type1,11-HSD1）O的活性的本发明11β-羟基类固醇脱氢酶类型1由式（1）刚刚杂环羧酰胺衍生物具有丁基，他的专业表示 其药学上可接受的盐，其制备方法以及含有该化合物作为活性成分的药物组合物。 其中W，X，R，R，L，a和b如式（1）的详细描述中所定义。
-
公开(公告)号：KR101569164B1
公开(公告)日：2015-11-13
申请号：KR1020140078590
申请日：2014-06-26
Applicant: 한국화학연구원
Abstract: 본발명은 PHA 검출용조성물, 이를이용한 PHA 염색방법, PHA 검출방법, PHA 합성관련유전자의스크리닝방법, 및배양조건변화에따른고수율의 PHA 생산방법에관한것으로, 시료에포함된 PHA만을특이적으로염색시켜 PHA의유무를판별하고 PHA의양을정량적으로측정할수 있으며, 미생물또는식물의성장을저해하거나미생물고정, 세포벽을파괴하기위한별도의전처리없이도살아있는생물체에서 PHA 합성과동시에 PHA의양을측정할수 있어, PHA 고생산성균주또는식물개발을위한유전자라이브러리의고속대량검출(High Throughput Screening)에활용할수 있다.
Abstract translation: 本发明涉及用于检测聚羟基链烷酸酯（PHA）的组合物，使用其的PHA染色方法，PHA检测方法，用于筛选与PHA合成相关的基因的方法，以及根据 培养条件的变化。 根据本发明，本发明的组合物确保PHA含量的定量测定，并且通过专门染色样品中所含的PHA来测定PHA的存在。 此外，组合物使得可以在活体中合成PHA的同时测量PHA的量，而不需要额外的预处理来抑制微生物或植物的生长，固定微生物和破坏细胞壁，从而适用于高通量筛选 用于开发高度产生PHA的菌株或植物的基因文库。
-
公开(公告)号：KR101465234B1
公开(公告)日：2014-12-01
申请号：KR1020110029772
申请日：2011-03-31
Applicant: 한국화학연구원
IPC: C07C311/43 , C07C311/41 , A61K31/18 , A61P3/10
Abstract: 본발명은하기화학식 1 표시되는, 사이클로프로필기를갖는아릴설폰아마이드유도체또는이의약학적으로허용가능한염이제공된다. 이아릴설폰아마이드유도체는 11베타하이드록시스테로이드디하이드로게나이제유형1의 (11-hydroxystreroid dehydrogenase type1, 11-HSD1) 활성을억제하여, 11-HSD1에의해매개되는각종질환을치료하는데유용하다. 화학식 1
-
公开(公告)号：KR101343668B1
公开(公告)日：2013-12-20
申请号：KR1020110086553
申请日：2011-08-29
Applicant: 한국화학연구원
IPC: A61K31/404 , C07D209/04 , G01N33/15 , A61P3/00
Abstract: 본발명은지질만을특이적으로염색하는화합물을포함하는대사증후군치료약물의스크리닝키트및 이를이용하는대사증후군치료약물의스크리닝방법을제공한다. 본발명의화학식 1 또는 2로표시된 3-인돌리논유도체또는그의염은지방조직만을특이적으로높은민감도로염색하는특성이있어, 이를통해발생하는형광강도를측정하여광학적방법으로지방조직의양을확인할수 있다. 이방법은수술이나조직의추출없이도가능하므로, 실험용동물의불필요한희생을막을수 있으며, 생체내에서지방조직의이동및 생성, 소멸을장기간동안관찰할수 있다. 따라서본 발명의화학식 1 또는 2로표시된 3-인돌리논유도체또는그의염을포함하는스크리닝키트는대사증후군치료약물의개발에유용하게사용될수 있다.
-
公开(公告)号：KR1020130023635A
公开(公告)日：2013-03-08
申请号：KR1020110086553
申请日：2011-08-29
Applicant: 한국화학연구원
IPC: A61K31/404 , C07D209/04 , G01N33/15 , A61P3/00
Abstract: PURPOSE: A method for screening a therapeutic drug for metabolic syndrome using 3- indolinone derivatives is provided to specifically and sensitively stain only fat tissues, and to confirm the amount of fat tissues. CONSTITUTION: A method for screening a therapeutic drug for metabolic syndrome using 3-indolinone derivatives comprises: a step of administering an indolinone derivative and a candidate drug to an animal model; and a step of analyzing a fluorescence image of the animal model. A kit for screening a therapeutic drug for metabolic syndrome contains the indolinone derivative or a salt thereof.
Abstract translation: 目的：提供使用3-二氢吲哚酮衍生物筛选代谢综合征治疗药物的方法，以特异性地敏感地仅染色脂肪组织，并确认脂肪组织的量。 构成：使用3-二氢吲哚酮衍生物筛选代谢综合征治疗药物的方法包括：向动物模型施用吲哚啉酮衍生物和候选药物的步骤; 以及分析动物模型的荧光图像的步骤。 用于筛选代谢综合征治疗药物的试剂盒含有二氢吲哚酮衍生物或其盐。
-
Patent Agency Ranking
公开(公告)号：KR1020110028050A
公开(公告)日：2011-03-17
申请号：KR1020090085954
申请日：2009-09-11
Applicant: 한국화학연구원
IPC: C07D265/33 , C07D265/32 , A61K31/4965 , A61P19/10
CPC classification number: C07D213/50 , C07D213/89 , C07D239/26 , C07D241/12 , C07D295/088 , C07D333/22
Abstract: PURPOSE: A pharmaceutical composition containing indenone derivative for preventing or treating bone diseases is provided to suppress bone absorption of osteoclast. CONSTITUTION: An indenone derivative is denoted by chemical formula 1. In chemical formula 1, R1 is 5-10 cyclic heteroaryl of C6-C10 aryl, Y is CH, N, N+(-C1-C6alkyl) or N+(-O-). A pharmaceutical composition for preventing and treating bone diseases contains the indenone derivative and physiologically acceptable salt as an active ingredient. The bone diseases is osteoporosis, fracture, periodontal diseases, bone metastatic cancer, or rheumatoid arthritis.
Abstract translation: 目的：提供含有用于预防或治疗骨病的茚酮酮衍生物的药物组合物，以抑制破骨细胞的骨吸收。 在化学式1中，R1是C6-C10芳基的5-10个环状杂芳基，Y是CH，N，N +（ - C1-C6烷基）或N +（ - O-） 。 用于预防和治疗骨疾病的药物组合物含有茚酮酮衍生物和生理学上可接受的盐作为活性成分。 骨病是骨质疏松症，骨折，牙周病，骨转移性癌症或类风湿性关节炎。
-
公开(公告)号：KR101656834B1
公开(公告)日：2016-09-13
申请号：KR1020100069018
申请日：2010-07-16
IPC: A61K31/35 , A61K31/352 , A23L1/30
CPC classification number: A61K31/352 , A23L33/10 , A61K31/35
Abstract: 본발명은콜포신다로페이트(Colforsin Daropate)를포함하는골 질환의예방또는치료용약학적조성물에관한것으로서, 상세하게본 발명의약학적조성물은파골세포의분화및 이에의한골 흡수를억제하고, 조골세포의분화및 이의활성을촉진시켜, 골절및 골다공증과같은골 질환의예방또는치료용조성물, 및건강기능식품용조성물로유용하다.
-
18.发明公开스트렙토마이세스 에룸펜스 ＫＲＢ－００１ 균주 또는 이의 배양액을 유효성분으로 함유하는 잡초 방제용 제초제 조성물 审中-实审用于控制作物的组合物，包括结核分枝杆菌KRB-001或其文化作为活性成分
公开(公告)号：KR1020140073867A
公开(公告)日：2014-06-17
申请号：KR1020120141838
申请日：2012-12-07
Abstract: The present invention relates to a herbicide composition for weed control containing a novel strain of Streptomyces erumpens KRB-001 or a culture medium thereof as an active ingredient. Particularly, the novel strain of Streptomyces erumpens KRB-001 or a culture medium thereof in the present invention shows a significant weeding function as a result of foliage treatment against Gramineae weeds and broadleaf weeds, and thus can be practically used for a herbicide composition for weed control and a weed control method.
Abstract translation: 本发明涉及含有新型链霉菌链霉菌KRB-001或其培养基作为有效成分的杂草控制除草剂组合物。 特别地，本发明中的链霉菌KRB-001或其培养基的新菌株由于对禾本科杂草和阔叶杂草的叶面处理而显示出显着的除草功能，因此可用于杂草除草剂组合物 控制和杂草控制方法。
-
公开(公告)号：KR1020130120414A
公开(公告)日：2013-11-04
申请号：KR1020130045811
申请日：2013-04-25
IPC: C07D263/34 , C07D231/14 , A61K31/421 , A61P3/00
CPC classification number: C07D213/82 , A61K31/167 , A61K31/216 , A61K31/27 , A61K31/403 , A61K31/415 , A61K31/421 , A61K45/06 , C07B2200/07 , C07C237/04 , C07C237/12 , C07C237/22 , C07C271/22 , C07C2601/14 , C07D209/20 , C07D209/42 , C07D213/56 , C07D231/12 , C07D231/14 , C07D239/26 , C07D261/08 , C07D261/10 , C07D263/32 , C07D263/34 , C07D271/06 , C07D277/30 , C07D277/56 , C07D417/12
Abstract: The present invention relates to a beta alanine derivative, a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same as an active ingredient. The novel beta alanine derivative and a pharmaceutically acceptable salt thereof are used as a pharmaceutical composition for preventing or treating various lipid metabolic disorders selected among obesity, dyslipidemia, fatty liver, insulin resistance syndrome, and hepatitis by effectively suppressing the activities of DGAT1 which catalyzes a final step of synthesizing neural fats.
Abstract translation: 本发明涉及β-丙氨酸衍生物及其药学上可接受的盐，以及含有该丙氨酸衍生物的药物组合物作为活性成分。 新颖的β-丙氨酸衍生物及其药学上可接受的盐被用作药物组合物，用于通过有效抑制DGAT1的活性来预防或治疗选自肥胖，血脂异常，脂肪肝，胰岛素抵抗综合征和肝炎的各种脂质代谢紊乱 合成神经脂肪的最后一步。
-
公开(公告)号：KR1020120111965A
公开(公告)日：2012-10-11
申请号：KR1020120004235
申请日：2012-01-13
Applicant: 한국화학연구원
IPC: C07C311/59 , A61K31/13 , A61K31/18 , A61P3/10
CPC classification number: C07D417/04 , A61K31/18 , C07C307/10 , C07C2603/74 , C07D285/10 , C07D285/14 , C07D285/15 , C07D285/16 , C07D285/36 , C07D417/10 , C07D417/12
Abstract: PURPOSE: A sulfamie derivative is provided to have excellent restraining activity to 11B-hydroxysteroid dehydrogenase type 1 and to be useful for preventing and treating various diseases mediated by 11B-HSD1. CONSTITUTION: A sulfamie derivative and pharmaceutically acceptable salts thereof are represented by chemical formula 1. In chemical formula 1, R^1 is H, C1-6 alkyl, cyano C1-6 alkyl, C3-8 cycloalkyl, substituted or unsubstituted benzyl, phenylethyl, C1-6 alkoxycarbonyl, phenylacetyl, naphthyl, or aryl of substituted 5-10 membered ring, R^2 and R^3 is respectively C1-6 alkyl or C2-6 alkenyl or R^2 and R^3 forms a ring, R^4 and R^5 is respectively H or C1-C^ alkyl, R^6 is H, OH, COOR^7 or CONR^7R^7, R^7 is H or C1-6 alkyl, and n is an integer from 1-3.
Abstract translation: 目的：提供一种磺胺衍生物，对1型11B-羟类固醇脱氢酶具有优异的抑制活性，可用于预防和治疗11B-HSD1介导的各种疾病。 组成：氨基磺酸衍生物及其药学上可接受的盐由化学式1表示。在化学式1中，R 1是H，C 1-6烷基，氰基C 1-6烷基，C 3-8环烷基，取代或未取代的苄基，苯乙基 C 1-6烷氧基羰基，苯乙酰基，萘基或被取代的5-10元环的芳基，R 2和R 3分别是C 1-6烷基或C 2-6烯基，或者R 2和R 3形成环， R 4和R 5分别是H或C 1 -C 12烷基，R 6是H，OH，COOR 7或CONR 7 R 17，R 7是H或C 1-6烷基，n是 1-3的整数。
-
-
-
-
-
-
-
-
-
Search Results
54
records
(took 0.031 seconds)
